Across TCGA pan-cancer cohorts, PDE7A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PDE7A data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher PDE7A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PDE7A expression acts as an unfavorable survival marker, although some lineages such as GBM and LUAD show a favorable association.

GBM, HNSC, and LUAD are the cancer types where PDE7A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Quartile	All	0.455	0.214	.002	14	view →
HNSC	OS	Median	All	0.140	1.000	.017	13	view →
LUAD	OS	Quartile	All	1.000	0.736	.015	12	view →
CCRCC	OS	Median	All	0.659	1.000	.043	1	view →
LSCC	OS	Median	All	0.911	0.817	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: PDE7A tumor-vs-normal RNA expression · all PDE7A data types